Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 0 | 3 | +3 |
| Shares | 0 | 25.5K | +25.5K |
| Value | $0 | $163.0K | +$163.0K |
New holders (3)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Parsons Capital Management Inc | 15,000 | $96.0K | 0.01% |
| Tocqueville Asset Management L.P. | 10,000 | $64.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 462 | $3.00K | 0.00% |
Sold out (0)
Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
None.